Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05524662 · ClinicalTrials.gov registry record · NA
Clinical and Histological Evaluation of BTL-785F Device for Non-invasive Treatment of Face
A NA study, sponsored by BTL Industries.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT05524662: Completed NA study, sponsored by BTL Industries.
NCT05524662 is a NA study that has completed, run by BTL Industries. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05524662, a NA study, has completed, sponsored by BTL Industries.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study will evaluate the clinical efficacy, safety and the performance of the BTL-785-7 applicator of the BTL-785F system for non-invasive treatment of facial wrinkles and overall improvement of facial appearance.
Primary Outcome
Evaluation of the facial skin to assess the changes related to connective tissue structural proteins in the biopsies obtained from the treatment group and control. Subjects will have one 3 mm punch biopsy obtained at the baseline and subsequent biopsies at the follow-up visits.
Interventions
- DEVICE BTL-785-7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-06-15 |
| Est. Completion | 2023-03-31 |
| Phase | NA |
What the finished NCT05524662 record still lists
NCT05524662 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which BTL-785-7 is the first listed.
NCT05524662 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05524662 about?
NCT05524662 is a clinical study titled "Clinical and Histological Evaluation of BTL-785F Device for Non-invasive Treatment of Face". This study will evaluate the clinical efficacy, safety and the performance of the BTL-785-7 applicator of the BTL-785F system for non-invasive treatment of facial wrinkles and overall improvement of facial appearance.
What is the current status of trial NCT05524662?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2022-06-15. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT05524662?
The interventions under investigation include: BTL-785-7 (DEVICE).
Who is sponsoring clinical trial NCT05524662?
This trial is sponsored by BTL Industries, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05524662's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI